Overview

A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects

Status:
Completed
Trial end date:
2009-02-06
Target enrollment:
Participant gender:
Summary
GW642444 and GSK233705 are in development for treatment of Chronic Obstructive Pulmonary Disease. Development of these two inhaled drugs as a combination therapy would have potential for improved patient benefit as they both work through different mechanisms and the combined bronchodilatory effect might be additive. This study will look at the this combination, for the first time, in healthy Japanese subjects.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Cholinergic Agents
Cholinergic Antagonists